Skip to content
lifestyle.tweeternet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Adlai Nortye Ltd.
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
August 3, 2026
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
July 16, 2026
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
July 13, 2026
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
April 16, 2026
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
February 12, 2026